Last reviewed · How we verify
Enoxaparin Injectable Product
At a glance
| Generic name | Enoxaparin Injectable Product |
|---|---|
| Also known as | Lovenox |
| Sponsor | Valleywise Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum (NA)
- Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome (NA)
- A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery (PHASE2)
- Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients (PHASE4)
- Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients (PHASE2)
- Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study
- Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enoxaparin Injectable Product CI brief — competitive landscape report
- Enoxaparin Injectable Product updates RSS · CI watch RSS
- Valleywise Health portfolio CI